Berlin, Jordan

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 10,968

Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors

Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 3,308

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 2,824

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 1,713

Larotrectinib in Patients with TRK Fusion-Positive Solid Tumours: A Pooled Analysis of Three Phase 1/2 Clinical Trials

Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., et al. (2020) · The Lancet Oncology

Sarcoma Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 1,028

Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models

Schulte, M. L., Fu, A., Zhao, P., Li, J., Geng, L., Smith, S. T., Kondo, J., Coffey, R. J., Johnson, M. O., Rathmell, J. C., et al. (2018) · Nature Medicine

Amino Acid Enzymes and MetabolismCancer, Hypoxia, and Metabolism

Cited by 494

Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update

Baxter, N. N., Kennedy, E. B., Bergsland, E., Berlin, J., George, T. J., Gill, S., Gold, P. J., Hantel, A., Jones, L., Lieu, C., et al. (2022) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 367

Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer

Hecht, J. R., Mitchell, E., Neubauer, M. A., Burris, H. A., Swanson, P., Lopez, T., Buchanan, G., Reiner, M., Gansert, J., & Berlin, J. (2010) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 110

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Tolcher, A. W., Berlin, J. D., Cosaert, J., Kauh, J., Chan, E., Piha-Paul, S. A., Amaya, A., Tang, S., Driscoll, K., Kimbung, R., et al. (2017) · Cancer Chemotherapy and Pharmacology

TGF-β signaling in diseasesCancer Immunotherapy and Biomarkers

Cited by 105

Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review

Rahib, L., Fleshman, J. M., Matrisian, L. M., & Berlin, J. D. (2016) · JAMA Oncology

Pancreatic and Hepatic Oncology ResearchStatistical Methods in Clinical Trials

Cited by 73

A first-in-human phase I study of OPB-111077, a small-molecule STAT3 and oxidative phosphorylation inhibitor, in patients with advanced cancers

Tolcher, A., Flaherty, K., Shapiro, G. I., Berlin, J., Witzig, T., Habermann, T., Bullock, A., Rock, E., Elekes, A., Lin, C., et al. (2018) · The Oncologist

Cytokine Signaling Pathways and InteractionsLung Cancer Treatments and Mutations

Cited by 57

Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer

Cohen, A. S., Geng, L., Zhao, P., Fu, A., Schulte, M. L., Graves-Deal, R., Washington, M. K., Berlin, J., Coffey, R. J., & Manning, H. C. (2020) · Translational Oncology

Colorectal Cancer Treatments and StudiesCancer, Hypoxia, and Metabolism

Cited by 49

608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)

Park, W., Kasi, A., Spira, A. I., Berlin, J. D., Wang, J. S., Herzberg, B., Kuboki, Y., Kitano, S., Pelster, M., Goldman, J. W., et al. (2024) · Annals of Oncology

Protein Degradation and InhibitorsPancreatic and Hepatic Oncology Research

Cited by 46

Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy

Das, S., Ciombor, K. K., Haraldsdottir, S., Pumpalova, Y., Sahin, I. H., Pineda, G., Shyr, Y., Lin, E. P., Hsu, C.-Y., Chu, S.-K., et al. (2020) · The Oncologist

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 41

Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations.

Tolcher, A. W., Park, W., Wang, J. S., Spira, A. I., Janne, P. A., Lee, H.-J., Gill, S., LoRusso, P., Herzberg, B., Goldman, J. W., et al. (2023) · Journal of Clinical Oncology

Protein Degradation and InhibitorsPancreatic and Hepatic Oncology Research

Cited by 33

Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy.

Das, S., Ciombor, K. K., Haraldsdottir, S., Pumpalova, Y. S., Sahin, I. H., Shyr, Y., Chu, S.-K., Lin, E. P.-Y., Hsu, C.-Y., Goff, L. W., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 15

Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?

Thota, R., Maitra, A., & Berlin, J. D. (2017) · Pancreas

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 12